MAVIRET can now be used as an 8-week, once-daily paediatric granule formulation option in treatment-naïve, without cirrhosis or with compensated cirrhosis, chronic Hepatitis C paediatric. | June 22, 2022
/CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced Health Canada has approved SKYRIZI® (risankizumab), for the treatment.
AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology - read this article along with other careers information, tips and advice on BioSpace